EGFR and non-small cell lung carcinoma: Amivantamab (Rybrevant) was approved in 2021 for the treatment of NSCLC harboring EGFR exon 20 insertion mutations; this antibody is a humanized bispecific IgG1 mAb targeting both EGFR and MET receptors.